Ads by Google
The Expand-A-Lung Breathing Resistance Exerciser has been selected as the top choice for respiratory fitness training by LA Times. Jorge Brouwer, inventor of the most compact breathing exerciser, manufactures and markets the easy to use "Expand-A-Lung."
Researchers found that the activation of a molecular pathway important in stem cell and developmental biology leads to an increase in lung stem cells.
Two types of cancer-causing agents in cigarettes - a nicotine-derived chemical and polycyclic aromatic hydrocarbons (PAHs) are the main culprits in lung cancer. Exposure to tobaccosmoke - both mainstream and second-hand - is a leading cause of cancer death in the United States.
The type of non-small cell lung cancer (NSCLC) patients have may now influence their treatment regimen and, in turn, survival outcome.
While a previous study found that upfront gefitinib treatment considerably improved the outcomes for non-small-cell-lung-cancer, additional research is required before such a strategy can be used for routine treatment planning.
Patients who have undergone surgical procedures for the removal of lung cancer can tolerate and benefit from exercise regimens started just a month after surgery.
Lung cancer patients whose histology is factored into treatment decisions may fare better as a result.
Long-term clinical trial results that were presented last Friday at the 1st European Lung Cancer Conference demonstrate that MAGE-A3 ASCI (Antigen-Specific Cancer Immunotherapeutic), an immune-boosting treatment for lung cancer patients, reduces the risk of relapse after surgery to the same extent as chemotherapy.
Papers presented at the 1st European Lung Cancer Conference demonstrate that common viruses such as HPV may play a role in the development of lung cancer.
Findings support the role of inflammation in determining lung cancer risk, particularly among African-American women.
Alfacell's ONCONASE (ranpirnase) could be a promising radiation sensitizer for lung cancer treatment.
Scientists have identified a genetic variant that not only makes smokers more susceptible to nicotine addiction but also increases their risk of developing two smoking-related diseases, lung cancer and peripheral arterial disease.
Researchers say the finding of lung cancer genes is an important discovery because it can provide ways to prevent and offer treatment for lung cancer and explain why some smokers get the disease and other don't and how come people who never smoke can get lung cancer.
Accuray Incorporated announced that approximately 90 percent of CyberKnife centers worldwide are now treating lung cancer with the CyberKnife Robotic Radiosurgery System. The number of lung cancer patients is growing significantly as well, with more than 5,000 individuals receiving CyberKnife treaents to date.
Radiofrequency ablation greatly improves survival time from primary or metastatic inoperable lung tumors.
Lung cancer surgery risk is lower in teach hospitals. Patients cared for by hospitals with residents in training have a 17 percent less chance of dying after lung cancer surgery compared with patients undergoing surgery at non-teaching hospitals.
Researchers have discovered biomarkers that predict which patients with advanced non-small-cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex.
Researchers, comparing the accuracy of positron emission tomography (PET) and computed tomography (CT) in the characterization of lung nodules, found that PET was far more reliable in detecting whether or not a nodule was malignant.
Immunotec announced the successful completion of a multi-center randomized, double-blind clinical trial on cancer-related weight loss in lung cancer patients.
Transgene announces promising preliminary data from trial evaluating its therapeutic vaccine TG4010 as an adjunct to first line chemotherapy in patients with advanced non-small cell lung cancer.
Allos Therapeutics initiates patient enrollment in a Phase 2b, randomized, multi-center study comparing PDX and Tarceva in patients with Stage IIIB/IV non-small cell lung cancer.
Exelixis has initiated a phase 1/2 trial of XL184 in patients with non-small cell lung cancer who have had progressive disease while on a regimen containing erlotinib.